News

News & Events

News

news

04 June 2020

Da Volterra’s CEO, Florence Séjourné, part of an interactive, virtual panel discussion: “Shifting the Treatment Paradigm: New tools to tackle antimicrobial resistance” during the virtual edition of the 2020 BIO International Convention.

Moderator: Natalie Grover, Reporter, Endpoints News. Speakers: Oreola Donini, PhD, Chief Scientific Officer, Soligenix, Inc. Daria Hazuda, VP, Infectious Diseases…

more

Non classé

26 May 2020

New study published in the Journal of Infection Control & Hospital Epidemiology highlights the need for prevention of CDI, especially in patients with hematological malignancies

The Da Volterra team, along with fellow scientists, is glad to announce the publication of a new study in the…

more

news

19 May 2020

Da Volterra Announces the Publication of Four Abstracts in the 30th ECCMID Abstract Book

We are very happy to share our research with colleagues from around the world in one of the most comprehensive…

more

Non classé

21 April 2020

Da Volterra to present ‘The Perception of Quality of Life Among CDI Patients in the US’ at Peggy Lillis Foundation’ 2020 National C. diff Advocacy Summit on April 21 at 1:10pm EST

Lise Lurienne, Market Access Manager at Da Volterra, together with Pierre-Alain Bandinelli, Da Volterra CBO, presented the subject of quality…

more

Non classé

20 April 2020

New article published in the Journal of Hospital Infection highlights the need for prevention of CDI, especially in haematological patients undergoing induction chemotherapy in the USA

Da Volterra is pleased to present the latest publication of the team on the burden of Clostridioides difficile in patients…

more

news

09 April 2020

A Meta-Analysis of 23 Published Studies Demonstrates the Negative Impact of Antibiotics on the Efficacy of Immune Checkpoint Inhibitors in Non-Small-Cell Lung Cancer Patients

• The impact of antibiotics on the efficacy of immune checkpoint inhibitors (ICIs) was evaluated in 23 studies including 2,208…

more

news

11 February 2020

Da Volterra Announces Positive Top-line Results from a Phase 2 Clinical Trial Evaluating DAV132 in 260 Patients

   • First clinical study evaluating DAV132 in patients    • Primary endpoint met: DAV132 was safe for use in…

more

events

03 February 2020

Da Volterra’s CEO, Florence Séjourné, is attending BIO CEO in New York on Feb 10-11, 2020!

The BIO CEO & Investor Conference is one of the largest investor conferences focused on established and emerging publicly traded…

more

events

12 December 2019

Da Volterra’s CEO, Florence Séjourné, and CBO, Pierre-Alain Bandinelli, are attending J.P. Morgan Healthcare Conference in SFO!

The annual J.P. Morgan Healthcare Conference is the largest and most informative healthcare investment symposium in the industry, bringing together…

more

news

03 December 2019

Da Volterra Announces Positive Results of a Phase 1 Drug-Drug Interaction Study Demonstrating No Interaction Between DAV132 and Two Narrow Therapeutic Index Drugs

Paris (France), 3rd of December, 2019 – Da Volterra, a clinical-stage biopharmaceutical company developing innovative products to protect the intestinal…

more

page 1/9next